U.S. Markets closed
  • S&P 500

    3,821.35
    -20.59 (-0.54%)
     
  • Dow 30

    31,802.44
    +306.14 (+0.97%)
     
  • Nasdaq

    12,609.16
    -310.99 (-2.41%)
     
  • Russell 2000

    2,202.98
    +10.77 (+0.49%)
     
  • Crude Oil

    64.87
    -0.18 (-0.28%)
     
  • Gold

    1,680.70
    +2.70 (+0.16%)
     
  • Silver

    25.24
    -0.03 (-0.13%)
     
  • EUR/USD

    1.1854
    -0.0071 (-0.5927%)
     
  • 10-Yr Bond

    1.5960
    +0.0420 (+2.70%)
     
  • Vix

    25.47
    +0.81 (+3.28%)
     
  • GBP/USD

    1.3822
    -0.0006 (-0.0442%)
     
  • USD/JPY

    108.9380
    +0.5560 (+0.5130%)
     
  • BTC-USD

    50,947.24
    +92.13 (+0.18%)
     
  • CMC Crypto 200

    1,045.17
    +20.96 (+2.05%)
     
  • FTSE 100

    6,719.13
    +88.61 (+1.34%)
     
  • Nikkei 225

    28,743.25
    -121.07 (-0.42%)
     

Aclaris Therapeutics to Present at the Jefferies Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

WAYNE, Pa., May 26, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced that management will present a company overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 1:00 p.m. ET.

A live audio webcast of the presentation may be accessed through the Events section of Aclaris’ website, www.aclaristx.com. An archived version of the webcast will be available for 30 days.

About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a physician-led biopharmaceutical company committed to addressing the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company’s diverse and multi-stage portfolio includes one late-stage investigational drug candidate and a pipeline powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn or Twitter @aclaristx.

Aclaris Contact
investors@aclaristx.com